Table 3.

Univariate analysis of OS and PFS in nasal-type ENKTL.

	OS			PFS
	HR	95% CI	P	HR	95% CI	P
Age >60	1.013	0.532–1.931	0.968	1.048	0.567–1.937	0.882
ECOG PS ≥2	1.880	1.290–2.740	0.011*	1.996	1.410–2.826	0.003*
B symptoms	1.853	1.119–3.069	0.017*	1.786	1.130–2.823	0.013*
Elevated LDH	1.980	1.200–3.266	0.008*	2.258	1.427–3.574	0.001*
EBV-DNA positive	0.680	0.506–0.913	0.018*	0.622	0.47–0.825	0.001*
LTI	2.092	1.218–3.592	0.007*	1.721	1.065–2.782	0.027*
RLN	2.058	1.269–3.339	0.01*	1.926	1.230–3.014	0.004*
BM involvement	6.135	2.441–15.41	0.001*	7.223	3.068–17.008	0.0001*
PINK-E ≥ 2	1.685	1.288–2.204	0.003*	1.777	1.387–2.277	0.0001*
WBC( × 10^9L−1) <4	1.361	0.744–2.489	0.317	1.778	1.039–3.042	0.036*
Platelet( × 10^9L−1)<100	1.497	0.545–4.112	0.433	1.664	0.672–4.117	0.271
Hb<110 g/L	1.838	1.037–3.258	0.037*	2.513	1.498–4.215	0.0001*

Abbreviation: BM, bone marrow; EBV, Epstein–Barr virus; ECOG PS, Eastern Cooperative Oncology Group performance status; Hb, hemoglobin; LDH, lactate dehydrogenase; LTI, local tumor invasion; PINK-E, prognostic index of natural killer lymphoma with Epstein-Barr virus; RLN, regional lymph node; WBC, white blood cell.

* indicates significant difference at the 5% level.